The yearlong recusal, he said, would remove him from decisions on all the companies he received payments from, including six that he held a financial interest in while at New Enterprise Associates, all health care providers or lab testing companies that are overseen by the Centers for Medicare and Medicaid Services. He also listed several biotech   that he invested in through T. R. Winston   Co. a merchant bank. Financial disclosure documents show Dr. Gottlieb made more than $3 million during 2016 and through March 1 of this year, including $1. 85 million from T. R. Winston and $280, 000 for consulting for New Enterprise, according to the disclosures, which were reported earlier by The Wall Street Journal. 